T-CURX GmbH said it has completed the first closing of a $20 million (€17.7 million) Series A financing to accelerate the clinical development of its non-viral CAR-T programs in acute myeloid leukemia and solid tumors, while advancing proprietary technologies designed to enable non-viral, in vivo CAR-T generation.
The Series A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, alongside existing and new individual investors, the company said.
T-CURX, a privately held German biotech with operations in Würzburg and Munich, is advancing a portfolio of non-viral CAR-T technologies and clinical-stage pipeline programs. The company said the financing will support both its clinical CAR-T efforts and its broader technology work, including approaches that combine non-viral CAR-vector strategies with lipid nanoparticle (LNP) technologies to make CAR-T generation more economical and scalable.
The company was founded in 2017 and spun out of the laboratory of co-founder Prof. Michael Hudecek at the University of Würzburg. T-CURX’s platform uses virus-free gene transfer via the Sleeping Beauty transposon system to engineer patient T cells.
KEY QUOTES:
“I am very excited that T-CURX attracted such a high-profile, international investor’s syndicate, led by BiomedVC, for financing T-CURX`s non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively… It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable in vivo CAR-T generation, in order to ‘democratize’ CAR-T therapies for patients globally.”
Ulf Grawunder, PhD, Co-Founder And CEO, T-CURX
“I am thrilled about leading a highly dedicated international syndicate of early-stage investors from Europe and Asia in this Series A financing for T-CURX… We are very much looking forward to support T-CURX to achieve all of their therapeutic and commercial ambitions.”
Aristotelis Nastos, PhD, Managing Partner And Investment Director, BiomedVC
